| Price | $1.11 |
| Year Range | $1.11 – $4.11 |
| Market Cap | $147M |
| Industry | Drug Manufacturers |
What Is Organogenesis’s AI Stock Analysis?
Organogenesis’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Organogenesis’s momentum in near-real time.
Organogenesis (ORGO) has an AltIndex AI Score of 44/100, currently a Hold signal. The AI Score distills Organogenesis's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Organogenesis’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Organogenesis — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving ORGO’s AI Score?
Fundamentals
Revenue for the last quarter was $44M. This is an increase of 17.53% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 56.58%, which may be a cause for concern. Net income for the last quarter was $-99M. This represents a decrease of 76.89% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 957.70%, which may be a cause for concern. Ebitda for the last quarter was $-47M. This is an increase of -15.85% compared to the quarter before it, which is a positive sign of growth. However, compared to the same quarter last year, there is a decrease of 811.60%, which may be a cause for concern.
See Organogenesis’s earnings and insider transactions.
Technicals
Today's stock price is $1.11. This represents a decrease of 20.14% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 72.52%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $1.25, which is lower than the previous SMA10 of $1.27. This suggests a potential downward trend in price movement. The RSI is 73.3, indicating a potentially overbought (bearish) condition.
See the full technical analysis and price prediction.
Alternative data
The business outlook among employees at Organogenesis is low (an estimate of only 7% of employees have a positive outlook), a concerning sign. Add to that that the business outlook is down by -42% in the last couple of months, an even more concerning trend.
Explore Organogenesis’s job postings, web traffic and app downloads.
Frequently Asked Questions: Organogenesis AI Stock Analysis
Organogenesis's AltIndex AI Score is 44/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Organogenesis a Hold (44/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Organogenesis — company overview, fundamentals, technicals and alternative data, with a recommendation. See the ORGO AI Score or sign up to read the full thesis.
